IRLA IRulya Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662774 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-87.4%
TTM EPS YoY193.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-98.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets26.6%
Debt / equity—
Current ratio14.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.44x
Accruals ratio-55.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $35.38M | $18.59M | $9.45M | $25.18M | $60.80M |
| SG&A expense | $15.05M | $17.58M | $17.70M | $26.01M | $29.52M |
| Operating income | -$58.07M | -$57.28M | -$34.62M | -$52.02M | -$90.32M |
| Pretax income | -$80.77M | -$56.74M | -$31.58M | -$51.94M | -$89.94M |
| Income tax | $3.21M | $87,000 | -$197,000 | -$284,000 | $0 |
| Net income | -$83.98M | -$56.83M | -$31.39M | -$51.66M | -$89.94M |
| EBITDA | -$57.93M | -$57.10M | -$34.30M | -$51.81M | -$89.97M |
| EPS (basic) | -1.68 | -1.31 | -0.84 | -1.54 | -3.03 |
| EPS (diluted) | -1.68 | -1.31 | -0.84 | -1.54 | -3.03 |
| Weighted avg. shares (diluted) | 50.10M | 43.26M | 37.24M | 33.50M | 29.72M |
| Balance sheet | |||||
| Cash & equivalents | $5.81M | $6.21M | $20.75M | $44.58M | $69.72M |
| Short-term investments | $11.94M | $34.57M | $54.31M | $45.60M | $37.08M |
| Receivables | — | — | — | $0 | — |
| Current assets | $22.90M | $44.04M | $77.44M | $93.75M | $111.67M |
| PP&E, net | $595,000 | $315,000 | $234,000 | $393,000 | $263,000 |
| Goodwill | — | $0 | $17.62M | $0 | $0 |
| Intangibles | $67.82M | $60.05M | $63.67M | $5.90M | $0 |
| Total assets | $93.52M | $114.48M | $167.90M | $103.91M | $133.23M |
| Current liabilities | $43.23M | $7.28M | $9.57M | $3.07M | $14.22M |
| Short-term debt | $18.03M | $0 | — | — | — |
| Long-term debt | $0 | $14.32M | $13.43M | $0 | — |
| Total debt | $18.03M | $14.32M | $13.43M | $0 | — |
| Total liabilities | $129.24M | $84.33M | $82.82M | $3.32M | $14.64M |
| Shareholders' equity | -$35.71M | $30.15M | $85.08M | $100.59M | $118.59M |
| Net debt | $12.22M | $8.11M | -$7.32M | -$44.58M | — |
| Shares outstanding | 278,627 | 44.00M | 42.97M | 36.14M | 30.07M |
| Cash flow statement | |||||
| Operating cash flow | -$41.42M | -$31.90M | -$18.29M | -$44.04M | -$62.93M |
| Capital expenditure | $352,000 | $257,000 | $160,000 | $133,000 | $180,000 |
| Free cash flow | -$41.78M | -$32.16M | -$18.45M | -$44.17M | -$63.11M |
| Investing cash flow | $23.23M | $21.91M | -$5.76M | $18.00M | $58.95M |
| Financing cash flow | $17.91M | -$4.78M | $143,000 | $707,000 | $6.81M |
| Depreciation & amortization | $142,000 | $186,000 | $322,000 | $204,000 | $344,000 |
| Stock-based compensation | $5.11M | $4.75M | $5.22M | $16.62M | $29.85M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.